Formulation development and pharmacokinetic studies of long acting in situ depot injection of risperidone
DOI:
https://doi.org/10.1590/s2175-97902022e18809Keywords:
Rape flower, Rapeseed, BPH, LUTS, TGF-β1Abstract
Risperidone is an atypical antipsychotic drug widely prescribed all over the world due to its clinical advantages. The currently available long acting marketed depot formulation of risperidone is a microsphere based preparation using poly-[lactide-co-glycolide] (PLGA) as drug release barrier. It is however, a cold chain product due to thermal instability of PLGA at room temperature. After beginning the depot injection therapy it is administered every two weeks but associated with another drawback of about 3 weeks lag time due to which its tablets are also administered for three weeks so as to attain and maintain therapeutic drug concentration in the body. The present work attempts to develop a long acting depot delivery system of risperidone for once a month administration based on the combination of sucrose acetate isobutyrate and polycaprolactone dissolved in benzyl benzoate to provide an effective drug release barrier for one month without any lag time and which can be stored at room temperature precluding the requirement of cold supply chain. The developed depot formulation showed a sustained in vitro drug release profile with 88.95% cumulative drug release in 30 days with little burst release. The in vivo pharmacokinetic studies of the developed formulation conducted on rats showed attainment of mean peak plasma drug concentration of 459.7 ng/mL in 3 days with a mean residence time of 31.2 days, terminal half-life of 20.6 days, terminal elimination rate constant of 0.0336 per day, and a good in vitro- in vivo correlation.
Downloads
References
Agarwal P, Rupenthal ID. Injectable implants for the sustained release of protein and peptide drugs. Drug Discov Today. 2013;18(7-8):337-349.
Arthur JT. Sucrose acetate isobutyrate (SAIB) for parenteral delivery. In: Rathbone MJ, Hadgraft J, Roberts MS, editors. Modified-release drug delivery technology. 2nd ed. New York: Marcel Dekker Inc; 2002. p. 679-687.
Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37(6):243-265.
Chien YW. Parenteral controlled-release drug administration. In: Chien YW, editor. Novel drug delivery systems. New York: Marcel Dekker Inc .; 1982. p. 219-310.
Cilurzo F, Selmin F, Minghetti P, Adami M, Bertoni E, Lauria S, et al. Injectability Evaluation: An Open Issue. AAPS PharmSciTech. 2011;12(2):604-609.
Conti B, Genta I, Giunchedi P, Modena T. Testing of in vitro dissolution behaviour of microparticulate drug delivery systems. Drug Develop Ind Pharm. 1995;21(10):1223-1233.
D’Souza S, Faraj JA, Giovagnoli S, Deluca PP. Development of risperidone PLGA microspheres. J Drug Deliv. 2014;2014:620464.
Dasaratha Dhanaraju M, Vema K, Jayakumar R, Vamsadhara C. Preparation and characterization of injectable microspheres of contraceptive hormones. Int J Pharm. 2003;268(1-2):23-29.
Dong WY, Korber M, Lopez Esguerra V, Bodmeier R. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. J Control Release. 2006;115(2):158-167.
Dubey V, Saini TR. Development of long acting depot injection of iloperidone by SABER® technology. Indian J Pharm Sci. 2018a;80(5):813-819.
Dubey V, Saini TR. A validated reverse phase-HPLC method for quantification of risperidone in rat plasma by PDA detector. Eur J Biomed Pharm Sci. 2018b;5(2):1171-1175.
Dubey V, Saini TR. Formulation and in vivo pharmacokinetic studies of iloperidone depot injection. Acta Pol Pharm. 2019;76(1):59-66.
DURECT Corporation. POSIMIR® (SABER®-Bupivacaine). 2017 [cited 2017 May 12]. Available from: Available from: http://www.durect. com/pipeline/development/posimir/
» http://www.durect. com/pipeline/development/posimir/
Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70(1):91-100.
Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48(2):253-273.
Gulati N, Gupta H. Parenteral drug delivery: A review. Recent Pat Drug Deliv Formul. 2011;5(2):133-145.
Hassan MMA, Mossa JS. Benzyl benzoate. In: Florey K, Bishara R, Brewer GA, Fairbrother JE, Grady LT, Leemann H-G et al., editors. Analytical profiles of drug substances. New York: Academic Press; 1981. p. 55-74.
Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release . 2002;80(1-3):9-28.
Heller M, Veach LM. Administration of parenteral medications. Clinical medical assisting: A professional, field smart approach to the workplace. 1st ed. Boston: Cengage Learning; 2008. p. 851-852.
Hu Z, Liu Y, Yuan W, Wu F, Su J, Jin T. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres. Colloids Surf B Biointerfaces. 2011;86(1):206-211.
ICH-Guidelines. Stability testing of new drug substances and products, Q1A (R2). 2003 [cited 2017 Jun 12]. Available from: Available from: https://www.ich.org/fileadmin/Public_Web_Site/ ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_ R2__Guideline.pdf
» https://www.ich.org/fileadmin/Public_Web_Site/ ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_ R2__Guideline.pdf
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: Epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216-226.
Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171-1180.
Kempe S, Mader K. In situ forming implants - an attractive formulation principle for parenteral depot formulations. J Control Release . 2012;161(2):668-679.
Lin X, Xu Y, Tang X, Zhang Y, Chen J, Zhang Y, et al. A uniform ultra-small microsphere/SAIB hybrid depot with low burst release for long-term continuous drug release. Pharm Res. 2015;32(11):3708-3721.
Lin X, Yang S, Gou J, Zhao M, Zhang Y, Qi N, et al. A novel risperidone-loaded SAIB-PLGA mixture matrix depot with a reduced burst release: Effects of solvents and PLGA on drug release behaviors in vitro/in vivo. J Mater Sci Mater Med. 2012;23(2):443-455.
Lu Y, Yu Y, Tang X. Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release. J Pharm Sci. 2007;96(12):3252-3262.
Masaro L, Zhu XX. Physical models of diffusion for polymer solutions, gels and solids. Prog Polym Sci. 1999;24(5):731-775.
Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long- acting injectable antipsychotics vs oral. J Med Econ. 2013;16(2):231-239.
Okumu FW, Dao le N, Fielder PJ, Dybdal N, Brooks D, Sane S, et al. Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials. 2002;23(22):4353-4358.
Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm. 2004;58(2):445-455.
Patrício T, Bártolo P. Thermal stability of PCL/PLA blends produced by physical blending process. Procedia Engineering. 2013;59:292-297.
Pohlmann AR, Fonseca FN, Paese K, Detoni CB, Coradini K, Beck RC, et al. Poly(-caprolactone) microcapsules and nanocapsules in drug delivery. Expert Opin Drug Deliv. 2013;10(5):623-638.
Prescott JH, Krieger TJ, Lipka S, Staples MA. Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multi-reservoir array. Pharm Res. 2007;24(7):1252-1261.
PrescribingInformation. Risperdal Consta®. Janssen Pharmaceuticals Inc. 2007.
ProductMonograph. Risperdal Consta®. Janssen Inc. 2004 [cited 2019 May 15]. Available from: Available from: http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/ live/risperdal_consta_cpm
» http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/ live/risperdal_consta_cpm
Rawat A, Stippler E, Shah VP, Burgess DJ. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta. Int J Pharm . 2011;420(2):198-205.
Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247.
Shen J, Burgess DJ. In vitro-in vivo correlation for complex non-oral drug products: Where do we stand? J Control Release . 2015;219:644-651.
Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21(2):201-230.
Su Z, Sun F, Shi Y, Jiang C, Meng Q, Teng L, et al. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide- co-glycolide) microsphere. Chem Pharm Bull (Tokyo). 2009;57(11):1251-1256.
Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: Routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50(5):600-613.
Ulery BD, Nair LS, Laurencin CT. Biomedical Applications of Biodegradable Polymers. Journal of polymer science. Part B, Polymer physics. 2011;49(12):832-864.
Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: A retrospective review. J Clin Psychiatry. 2006;67(10):1542-1550.
Wang L, Wang A, Zhao X, Liu X, Wang D, Sun F, et al. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism. Int J Pharm . 2012;427(2):284-292.
Woodruff MA, Hutmacher DW. The return of a forgotten polymer-Polycaprolactone in the 21st century. Prog Polym Sci . 2010;35(10):1217-1256.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
